Sweden
· Delayed Price · Currency is SEK Diamyd Medical AB Statistics
Total Valuation
Diamyd Medical AB has a market cap or net worth of SEK 1.44 billion. The enterprise value is 1.28 billion.
| Market Cap | 1.44B |
| Enterprise Value | 1.28B |
Important Dates
The next estimated earnings date is Wednesday, October 9, 2024.
| Earnings Date | Oct 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Diamyd Medical AB has 99.72 million shares outstanding. The number of shares has increased by 17.16% in one year.
| Shares Outstanding | 99.72M |
| Shares Change (YoY) | +17.16% |
| Shares Change (QoQ) | +1.75% |
| Owned by Insiders (%) | 15.65% |
| Owned by Institutions (%) | 14.68% |
| Float | 82.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 7.39 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -8.88 |
Financial Position
The company has a current ratio of 8.87
| Current Ratio | 8.87 |
| Quick Ratio | 8.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -66.30 |
Financial Efficiency
Return on equity (ROE) is -84.24% and return on invested capital (ROIC) is -52.08%.
| Return on Equity (ROE) | -84.24% |
| Return on Assets (ROA) | -42.65% |
| Return on Capital (ROIC) | -52.08% |
| Revenue Per Employee | 7,400 |
| Profits Per Employee | -5.58M |
| Employee Count | 25 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +79.88% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +79.88% |
| 50-Day Moving Average | 16.17 |
| 200-Day Moving Average | 12.64 |
| Relative Strength Index (RSI) | 45.18 |
| Average Volume (20 Days) | 200,885 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diamyd Medical AB had revenue of SEK 185,000 and -139.62 million in losses. Loss per share was -1.55.
| Revenue | 185,000 |
| Gross Profit | -3.72M |
| Operating Income | -138.10M |
| Pretax Income | -139.62M |
| Net Income | -139.62M |
| EBITDA | -132.68M |
| EBIT | -138.10M |
| Loss Per Share | -1.55 |
Balance Sheet
| Cash & Cash Equivalents | 162.38M |
| Total Debt | n/a |
| Net Cash | 162.38M |
| Net Cash Per Share | 1.63 |
| Equity (Book Value) | 195.45M |
| Book Value Per Share | 1.96 |
| Working Capital | 162.76M |
Cash Flow
In the last 12 months, operating cash flow was -134.54 million and capital expenditures -9.83 million, giving a free cash flow of -144.37 million.
| Operating Cash Flow | -134.54M |
| Capital Expenditures | -9.83M |
| Free Cash Flow | -144.37M |
| FCF Per Share | -1.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | -74,649.73% |
| Pretax Margin | -75,471.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -78,038.92% |
Dividends & Yields
Diamyd Medical AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.16% |
| Shareholder Yield | -17.16% |
| Earnings Yield | -10.67% |
| FCF Yield | -10.00% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Diamyd Medical AB has an Altman Z-Score of 6.37.
| Altman Z-Score | 6.37 |
| Piotroski F-Score | n/a |